Canal P - Search Results

1

Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation.

Schlaifer D, Attal M, Huguet F, Canal P, Laurent G, Pris J. Schlaifer D, et al. Among authors: canal p. Semin Hematol. 1994 Apr;31(2 Suppl 3):31. Semin Hematol. 1994. PMID: 8073306 No abstract available.

2

Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.

Attal M, Canal P, Schlaifer D, Chatelut E, Dezeuze A, Huguet F, Payen C, Pris J, Laurent G. Attal M, et al. Among authors: canal p. J Clin Oncol. 1994 Jan;12(1):141-8. doi: 10.1200/JCO.1994.12.1.141. J Clin Oncol. 1994. PMID: 8270970 Clinical Trial.

3

Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases.

de Forni M, Lachau S, Huguet F, Canal P, Laurent G, Chevreau C, Roche H, Bugat R. de Forni M, et al. Among authors: canal p. Eur J Cancer. 1991;27(6):735-9. doi: 10.1016/0277-5379(91)90177-f. Eur J Cancer. 1991. PMID: 1829914

4

Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion.

Muller C, Chatelut E, Gualano V, De Forni M, Huguet F, Attal M, Canal P, Laurent G. Muller C, et al. Among authors: canal p. Cancer Chemother Pharmacol. 1993;32(5):379-84. doi: 10.1007/BF00735923. Cancer Chemother Pharmacol. 1993. PMID: 8339389

5

Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas.

Canal P, Attal M, Chatelut E, Guichard S, Huguet F, Muller C, Schlaifer D, Laurent G, Houin G, Bugat R. Canal P, et al. Cancer Res. 1993 Oct 15;53(20):4850-4. Cancer Res. 1993. PMID: 8402672 Clinical Trial.

6

Characterization and chemosensitivity of a human epithelioid sarcoma cell line (SARCCR 2).

Roché H, Julia AM, Jozan S, Muller C, Dastugue N, Arquier MA, Marques B, Laurent G, Canal P. Roché H, et al. Among authors: canal p. Int J Cancer. 1993 Jun 19;54(4):663-8. doi: 10.1002/ijc.2910540423. Int J Cancer. 1993. PMID: 8099901

7

Atypical protein kinase C stimulates nucleotide excision repair activity.

Louat T, Canitrot Y, Jousseaume S, Baudouin C, Canal P, Laurent G, Lautier D. Louat T, et al. Among authors: canal p. FEBS Lett. 2004 Sep 10;574(1-3):121-5. doi: 10.1016/j.febslet.2004.08.024. FEBS Lett. 2004. PMID: 15358551 Free article.

8

Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma.

Chatelut E, Chevreau C, Blancy E, Lequellec A, Canal P, Roche H, Houin G, Bugat R. Chatelut E, et al. Among authors: canal p. Cancer Chemother Pharmacol. 1990;26(5):365-8. doi: 10.1007/BF02897295. Cancer Chemother Pharmacol. 1990. PMID: 2170043

9

Population pharmacokinetics of total and unbound etoposide.

Nguyen L, Chatelut E, Chevreau C, Tranchand B, Lochon I, Bachaud JM, Pujol A, Houin G, Bugat R, Canal P. Nguyen L, et al. Among authors: canal p. Cancer Chemother Pharmacol. 1998;41(2):125-32. doi: 10.1007/s002800050718. Cancer Chemother Pharmacol. 1998. PMID: 9443625

10

Chronopharmacokinetics of doxorubicin in patients with breast cancer.

Canal P, Sqall A, de Forni M, Chevreau C, Pujol A, Bugat R, Roche H, Oustrin J, Houin G. Canal P, et al. Eur J Clin Pharmacol. 1991;40(3):287-91. doi: 10.1007/BF00315211. Eur J Clin Pharmacol. 1991. PMID: 2060566 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

168 results

Search Page

Filters